← Leaderboards
Jeffrey R Wilson
Cleveland Clinic Lerner Com-Cwru
$1,157,806
Attributed
$3,473,418
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2021–23$2M$1.5M$1M$500K$0
'21
'22
'23
Funding mix
By agency
NIH$3,473,418 · 2
By mechanism
R01$3,473,418 · 2
Top collaborators
- Boris Decourt5 shared
- Marwan Noel Sabbagh5 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Nicola Marchi$850,868
- Mina Kay Chung$7,078,575
- Jaroslaw P Maciejewski$28,244,801
- James Matthew Hiznay$128,703
- Hamlet Gasoyan$658,016
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposNeuropathologyBloodInflammatoryMild Cognitive ImpairmentNeuroinflammationClinical ResearchDesignFda ApprovedInflammationBrainAnalogAdverse EventMonitorDoseAnti-Inflammatory AgentsClinical TrialsCognitionAmyloid Beta-ProteinEnzyme-Linked Immunosorbent AssayImmunomodulatorsImpaired CognitionLenalidomidePeripheral
Grant awards (5)
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$701,731
R01 · FY2023 · AG
Repurposing Siponimod for Alzheimer's Disease$687,290
R01 · FY2023 · AG
Repurposing Siponimod for Alzheimer's Disease$688,670
R01 · FY2022 · AG
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$663,871
R01 · FY2022 · AG
Repurposing Siponimod for Alzheimer's Disease$731,856
R01 · FY2021 · AG